Rinvoq for Rheumatoid Arthritis: An Innovative Treatment Option
Rinvoq (upadacitinib) is a medication used to treat adults with rheumatoid arthritis (RA) who have not completely responded to conventional treatments. It works by inhibiting certain proteins in the body that are involved in inflammation. This helps reduce the intensity of a person’s pain and slows the progression of their RA.
Rinvoq is a type of drug known as a Janus Kinase (JAK) inhibitor and is considered to be a significant advance in the treatment of RA. It can be taken in either 15mg or 30mg doses, once per day and is taken orally. Studies have shown that it can reduce the signs and symptoms of RA significantly more than the conventional treatments available.
It was approved by the United States Food and Drug Administration (FDA) in 2019 and is currently available for prescription in the US. Rinvoq is generally reserved for more severe cases of RA, where other treatments have failed.
The side effects of this medication may include nausea, some diarrhea, and upper respiratory infections. The potential for serious side effects from Rinvoq is considered to be low and it is generally safe to use. It is important to consult with a doctor before beginning treatment, however, and to follow their directions closely.
All in all, Rinvoq is a promising and innovative treatment option for those suffering from RA. If a person has not been able to find relief with other treatments, it can be an effective solution for them. It is important to note that it does not cure RA and must be taken indefinitely, but it can help to reduce pain and slow the progression of the disease.